FOR NOVARTIS CLINICAL OPERATIONS
Global Trials.
One quality standard.
Zero fragmentation.
Novartis runs some of the most complex clinical programs in the world. We know, because we work alongside your teams every day. This page was built for you: three things that matter most when language and content operations have to keep pace with your ambition.
01 Quality
02 Scalability
03 Partnership
WHY THIS PAGE
Running oncology, rare disease, and gene therapy programs across dozens of markets means managing extraordinary complexity. When clinical content workflows are disconnected across CROs, affiliates, and translation partners, quality risk compounds at every handoff. GCP compliance, consistency across markets, and trial timelines all suffer. Here is how Welo Life Sciences helps Novartis teams solve it.
OUR APPROACH
Three commitments to your clinical teams
Not capabilities. Not features. Commitments: measurable, accountable, and specific to the complexity of global clinical operations.
Quality
GCP compliance is not a checkbox. It is a discipline embedded at every layer of our clinical translation workflow. We treat quality as an operational standard, not a QA afterthought.
- ISO 17100 and ISO 9001 certified clinical translation processes
- GCP-trained linguists across all major therapeutic areas
- Regulatory submission track record: FDA, EMA, PMDA
- Structured QM reviews with documented error metrics
- Consistency protocols across long-running trial programs
Scalability
Global trials do not wait. When Novartis expands into a new market or accelerates a program, language operations need to move at the same speed without sacrificing quality standards.
- 300+ languages supported with clinical-grade coverage
- Surge capacity protocols for fast-expanding programs
- AI-assisted workflows with human expert oversight
- Platform interoperability with major clinical systems
- Integrated model with no fragmented vendor handoffs
Partnership
A language vendor plugged in at the end of a workflow is a vendor. A partner is embedded in your clinical operations: understanding your programs, your timelines, and your risk tolerance before a document ever lands.
- Dedicated clinical account teams with therapeutic area expertise
- Governance structures built around Novartis workflows
- SLA performance reviewed transparently every quarter
- Proactive program planning, not just reactive delivery
- Single point of accountability across all markets
300+
Languages with clinical-grade coverage
99.2%
On-time delivery rate across clinical programs
25+
Years supporting regulated life sciences content
Top 10
Global pharma companies served by our clinical teams
CLINICAL CASE STUDY
Reducing quality risk across a global Phase III oncology program
A top-10 global pharmaceutical sponsor faced mounting quality and consistency challenges across a 40-market Phase III oncology trial. Fragmented vendors, inconsistent terminology, and manual handoffs were creating compliance risk and delaying regulatory submissions. Welo Life Sciences implemented an integrated clinical language operations model, consolidating delivery, standardizing terminology, and embedding QM into every workflow stage.
“We stopped thinking of them as a translation supplier. They became part of our clinical operations infrastructure, anticipating problems before they reached us.”
VP Clinical Operations, Global Top-10 Pharma Sponsor
43%
Reduction in quality review cycles
18
Days faster to regulatory submission on average
100%
GCP audit pass rate across all markets
40
Markets supported through a single governance model
WHY WELO LIFE SCIENCES
How we compare for clinical operations
Not all language service providers are built for the complexity of global clinical programs. Here is the distinction that matters.
YOUR WELO LIFE SCIENCES CONTACT
Marta Motta
Director of Global Client Solutions
Marta works directly with global clinical operations teams and would welcome a focused conversation about Novartis’s specific priorities. No pitch decks, no generic presentations: just a direct discussion about what matters most to your team right now.
GET IN TOUCH
Ready to talk?
A focused conversation with Marta about Novartis’s clinical language operations priorities.